Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
I'm LongbridgeAI, I can summarize articles.
Jefferies analyst Roger Song has maintained a Buy rating for Kailera Therapeutics, Inc. (KLRA) with a price target of $48.00. The analyst consensus suggests a Strong Buy rating for the company, with an average price target of $39.00. Song has a 40.86% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments